Tekla Life Sciences Investors
HQL · NYSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $366 | $434 | $369 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $366 | $434 | $369 |
| Revenue | – | $18 | $2 | $2 |
| % Growth | – | 850.5% | -7.3% | – |
| Gross Profit | – | $0 | $2 | $2 |
| % Margin | – | 0% | 100% | 100% |
| EBITDA | – | -$47 | $0 | $101 |
| % Margin | – | -259.5% | 0% | 4,898.5% |
| Net Income | – | -$47 | $35 | $50 |
| % Margin | – | -259.5% | 1,830% | 2,433.4% |
| EPS Diluted | – | -1.64 | 1.22 | 1.84 |
| % Growth | – | -234.4% | -33.7% | – |
| Operating Cash Flow | – | -$1 | – | – |
| Capital Expenditures | – | -$0 | – | – |
| Free Cash Flow | – | -$1 | – | – |